{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_metadata=all&version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "items" : [{"_about" : "http://data.parliament.uk/resources/780519", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/780519/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) encourages anyone to report a suspected adverse reaction (ADR) to a vaccine or medicine through the Yellow Card Scheme:<\/p><p> <\/p><p><a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard<\/a><\/p><p>A Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine or medicine may have been the cause. Such reports are kept under continual review to identify potential new risks.<\/p><p> <\/p><p>Between 31 October 2014 \u2013 30 October 2017 a total of 649 serious suspected adverse reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme (data run date: 1 November 2017). In this three year period, at least 1 million doses of HPV vaccine were administered in the United Kingdom.<\/p><p> <\/p><p>A breakdown of UK serious suspected spontaneous ADR reports received via the Yellow Card Scheme beween 31 October 2014 \u2013 30 October 2016 by brand and year received is shown in the following table.<\/p><p> <\/p><table><tbody><tr><td><p>HPV Vaccine<\/p><\/td><td><p>Number of serious reports<\/p><\/td><\/tr><tr><td><p>HPV brand unspecified<\/p><\/td><td><p>181<\/p><\/td><\/tr><tr><td><p>Cervarix<\/p><\/td><td><p>64<\/p><\/td><\/tr><tr><td><p>Gardasil<\/p><\/td><td><p>390<\/p><\/td><\/tr><tr><td><p>Gardasil 9<\/p><\/td><td><p>18<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>649<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p>Source: MHRA sentinel database for adverse reactions<\/p><p> <\/p><p>Notes:<\/p><p> <\/p><p>The total number of reports received by vaccine brand is not equal to the totals in the table above as some reports included more than one HPV vaccine brand.<\/p><p> <\/p><p>The MHRA has received a total of 3,159 serious suspected adverse reaction reports associated with HPV vaccine (data run date 1 November 2017).<\/p><p> <\/p><p>All serious reports received via the Yellow Card Scheme are reviewed based on the details received from the reporter. Follow up letters may be sent for missing information such as vaccine brand name, batch number, medical history, results of investigations, diagnoses and details of outcome.<\/p><p> <\/p><p>The Commission on Human Medicines has thoroughly reviewed the safety of HPV vaccines and concluded that the evidence does not support a link between HPV vaccination and the development of chronic illnesses.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2017-11-07", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "110248"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-11-07T11:31:40.833Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-10-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how many Yellow Cards submitted to the Medicines and Healthcare Products Regulatory Agency for the HPV vaccination were classified as serious; and how many of those cases were reviewed to establish whether the patient had returned to full health in each of the last 12 months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4663", "label" : {"_value" : "Biography information for Ben Bradley"}
      }
      , "tablingMemberConstituency" : {"_value" : "Mansfield"}
      , "tablingMemberPrinted" : [{"_value" : "Ben Bradley"}
      ], "uin" : "110360"}
    , {"_about" : "http://data.parliament.uk/resources/642297", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/642297/answer", "answerText" : {"_value" : "<p>The Joint Committee on Vaccination and Immunisation (JCVI), advises Ministers on immunisation related issues, is currently in the process of considering the impact and cost-effectiveness of extending the human papillomavirus (HPV) vaccination to adolescent boys.<\/p><p> <\/p><p>The JCVI will need to consider mathematical modelling by Public Health England (PHE) on the impact and cost effectiveness of extending the HPV vaccination to adolescent boys, ahead of developing its advice. PHE is expected to report its modelling assessment to the Committee in early 2017.<\/p><p> <\/p><p>The JCVI will consider the analysis from PHE at the earliest opportunity. Once the Committee is satisfied it has reviewed all the necessary evidence it will then be expected to make its advice.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
        , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
        , "dateOfAnswer" : {"_value" : "2016-11-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-11-30T17:59:22.647Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when the Joint Committee on Vaccination and Immunisation is expected to make a recommendation on the issuing of HPV vaccination for adolescent boys.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
      , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
      ], "uin" : "54217"}
    , {"_about" : "http://data.parliament.uk/resources/642302", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/642302/answer", "answerText" : {"_value" : "<p>The Secretary of State for Health is under the public sector equality duty (PSED) including in relation to policies such as new vaccination programmes. Complying with the PSED requires that there is consideration of equality issues during the decision making process and implementation. The consideration of such equality issues will take place as part of the policy making process concerning human papillomavirus (HPV) vaccination for boys.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
        , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
        , "dateOfAnswer" : {"_value" : "2016-11-30", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "54209"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-11-30T17:59:08.987Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what plans he has to conduct an equality impact assessment of HPV vaccination for boys; and whether any such assessment will take place before or after a recommendation from the Joint Committee on Vaccination and Immunisation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
      , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
      ], "uin" : "54216"}
    , {"_about" : "http://data.parliament.uk/resources/642305", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/642305/answer", "answerText" : {"_value" : "<p>The Secretary of State for Health is under the public sector equality duty (PSED) including in relation to policies such as new vaccination programmes. Complying with the PSED requires that there is consideration of equality issues during the decision making process and implementation. The consideration of such equality issues will take place as part of the policy making process concerning human papillomavirus (HPV) vaccination for boys.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
        , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
        , "dateOfAnswer" : {"_value" : "2016-11-30", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "54216"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-11-30T17:59:09.063Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether he has requested legal advice on whether HPV vaccination for boys is required under the terms of equality legislation; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
      }
      , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
      , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
      ], "uin" : "54209"}
    , {"_about" : "http://data.parliament.uk/resources/522153", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/522153/answer", "answerText" : {"_value" : "<p>Experience from the two Brent and Harrow clinics providing human papillomavirus vaccinations to men who have sex with men was shared with Public Health England and has helped to inform the development of the pilot. North West London is unlikely to be representative of England as a whole and the pilot will therefore let us consider provision of this vaccination programme in different geographical areas. It will also consider a wider age range than the service provided in these two clinics. The pilot will cover men up to 45 years of age in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI). The pilot will help resolve a range of implementation issues and determine whether a national programme can be delivered through Genito-Urinary Medicine and HIV clinics at a cost effective price in line with the JCVI\u2019s advice.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-06-10T10:59:07.483Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-05-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he made of the utility of data from the clinic in Brent and Harrow which has been providing men who have sex with men with HPV vaccinations since 2012 when determining that it was necessary to conduct an HPV vaccination pilot before deciding on a national roll-out; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4429", "label" : {"_value" : "Biography information for Mr William Wragg"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hazel Grove"}
      , "tablingMemberPrinted" : [{"_value" : "William Wragg"}
      ], "uin" : "38847"}
    , {"_about" : "http://data.parliament.uk/resources/521270", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/521270/answer", "answerText" : {"_value" : "<p>The Joint Committee on Vaccination and Immunisation (JCVI), the expert body that advises the Government on all immunisation matters, advised that a targeted human papillomavirus (HPV) vaccination programme should be undertaken for men who have sex with men (MSM) up to 45 years of age who attend genitourinary medicine and HIV clinics. They noted that this should be subject to procurement of the vaccine and delivery of the programme at a cost-effective price. JCVI acknowledged that finding a way to implement its advice would be challenging and made clear that work was needed by the Department and others to consider commissioning and delivery routes for this programme.<\/p><p>The Department announced on 26 May 2016 that an HPV vaccination pilot for MSM would start in June.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-06-02", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "38133"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-06-02T15:24:39.14Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-05-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether he plans for the HPV vaccination programme at sexual health clinics for men who have sex with men to be rolled out nationally at the earliest opportunity or to be implemented through initial pilot projects.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "38132"}
    , {"_about" : "http://data.parliament.uk/resources/514076", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/514076/answer", "answerText" : {"_value" : "<p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department\u2019s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department\u2019s policies.<\/p><p>The answer of 23 March 2016 stated, \u2018data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.\u2019 This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.<\/p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-04-25", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "34693"}
        , {"_value" : "34694"}
        , {"_value" : "34695"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-04-25T14:55:51.47Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-04-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department's policies of the 2016 paper by Mesher and others, Reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "34696"}
    , {"_about" : "http://data.parliament.uk/resources/475722", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/475722/answer", "answerText" : {"_value" : "<p>The Department and Public Health England are currently undertaking a procurement exercise to secure vaccine to support the human papillomavirus vaccination programme for girls. As this is a competitive tender, it would not be appropriate to discuss the outcome of the procurement until a contract has been concluded with the successful bidder following the mandatory standstill period.<\/p><p>The procurement will take account of the costs and benefits of all vaccines offered to establish which provides best value for money for the National Health Service. The award criteria are published on the government\u2019s Contracts Finder website:<\/p><p>https://www.contractsfinder.service.gov.uk/Notice/813bc859-8662-4c79-822b-f03cc84b8ceb<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-03-23", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "31112"}
        , {"_value" : "31115"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-23T15:25:52.247Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-03-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the decision making criteria is for the award of the contract for the supply of human papilloma virus vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31114"}
    , {"_about" : "http://data.parliament.uk/resources/475732", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/475732/answer", "answerText" : {"_value" : "<p>The Department has not estimated the impact on the incidence of recurrent respiratory papillomatosis if the bivalent vaccine replaces the quadrivalent vaccine in the human papillomavirus (HPV) vaccination programme for girls.<\/p><p>Warwick University is carrying out some limited analysis, in the context of its modelling work on the impact and cost effectiveness of extending HPV vaccination to boys, but the results are academically and commercially confidential, and subject to review by the Joint Committee on Vaccination and Immunisation, the independent expert body that advises Ministers on immunisation matters.<\/p><p>Estimates of the potential impact of the HPV vaccination programme on cancer and warts, including the incidence of recurrent respiratory papillomatosis, have been previously published by Public Health England in the British Medical Journal in 2011:<\/p><p>http://www.bmj.com/content/343/bmj.d5775<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-03-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-03-23T15:23:53.527Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-03-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made on the likely incidence of recurrent respiratory papillomatosis in the event that the (a) quadrivalent vaccine is maintained for UK HPV vaccination programme for girls and (b) bivalent vaccine is introduced for the UK HPV vaccination programme for girls.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/230", "label" : {"_value" : "Biography information for Mr Ben Bradshaw"}
      }
      , "tablingMemberConstituency" : {"_value" : "Exeter"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ben Bradshaw"}
      ], "uin" : "31120"}
    , {"_about" : "http://data.parliament.uk/resources/451411", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/451411/answer", "answerText" : {"_value" : "<p>In November 2015, the Joint Committee on Vaccination and Immunisation (JCVI), the expert body that advises the Government on all immunisation matters, advised that a targeted human papillomavirus vaccination programme should be undertaken for men who have sex with men up to 45 years of age who attend genitourinary medicine and HIV clinics. They noted that this should be subject to procurement of the vaccine and delivery of the programme at a cost-effective price.<\/p><p>JCVI acknowledged that finding a way to implement its advice would be challenging and made clear that work was needed by DH and others to consider commissioning and delivery routes for this programme. This work is already underway and we will announce our plans as soon as we can.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2016-02-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-02-09T15:04:57.27Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-02-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what progress his Department is making on rolling out HPV vaccinations to men who have sex with men.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4004", "label" : {"_value" : "Biography information for Mike Freer"}
      }
      , "tablingMemberConstituency" : {"_value" : "Finchley and Golders Green"}
      , "tablingMemberPrinted" : [{"_value" : "Mike Freer"}
      ], "uin" : "903556"}
    ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&version=2&hansardHeading=Human+Papillomavirus%3A+Vaccination&max-questionFirstAnswered.=2017-11-07T11%3A31%3A40.833Z", "page" : 0, "startIndex" : 1, "totalResults" : 12, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}